Literature DB >> 17379412

Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study.

Wim Opstelten1, Nicolaas P A Zuithoff, Gerrit A van Essen, Anton M van Loon, Albert J M van Wijck, Cornelis J Kalkman, Theo J M Verheij, Karel G M Moons.   

Abstract

Postherpetic neuralgia (PHN) is the most frequent complication of herpes zoster (HZ) and difficult to treat. Timely identification of high-risk HZ-patients enables physicians to focus on PHN prevention. To assess which simple to measure factors are independent predictors of PHN, and whether psychosocial and serological/virological parameters have additional predictive value, a prospective cohort study in primary care was conducted. We included 598 elderly (>50 years) consecutive patients with acute HZ (rash <7 days) below sixth cervical dermatome. At baseline demographic, clinical (e.g., duration and severity of pain and rash), psychological (Pain Cognition List [PCL] and Spielberger's Anxiety Inventory), serological (VZV-antibodies) and virological (viremia presence) variables were measured. Blood tests were performed in a random subset of 218 patients. Primary outcome was significant pain (VAS >30 on 0-100 scale) after three months. The final prediction model obtained from multivariable logistic regression was (internally) validated using bootstrapping techniques, and adjusted for optimism. Forty-six (7.7%) patients developed PHN. Independent predictors were age (odds ratio [OR]=1.08 per year), acute pain severity (OR=1.02 per unit), presence of severe rash (OR=2.31), and rash duration before consultation (OR=0.78 per day): area under receiver-operating-characteristic curve [ROC area]=0.77 (95% CI: 0.71-0.82). Of the five PCL scores, only factor V ('trust in healthcare') was an additional predictor (OR=1.01 per unit), though it increased the ROC area with only 0.01 to 0.78. The Spielberger's anxiety scores and serological and virological variables were no additional predictors. Thus, four simple variables can help physicians to timely identify elderly HZ-patients at risk of PHN.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379412     DOI: 10.1016/j.pain.2007.02.004

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  26 in total

1.  The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study.

Authors:  Mélanie Drolet; Marc Brisson; Kenneth E Schmader; Myron J Levin; Robert Johnson; Michael N Oxman; David Patrick; Caty Blanchette; James A Mansi
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

2.  Chronic Orofacial Pain: Burning Mouth Syndrome and Other Neuropathic Disorders.

Authors:  Raymond C Tait; McKenzie Ferguson; Christopher M Herndon
Journal:  J Pain Manag Med       Date:  2017-01-30

Review 3.  Treatment of herpes zoster.

Authors:  Wim Opstelten; Just Eekhof; Arie Knuistingh Neven; Theo Verheij
Journal:  Can Fam Physician       Date:  2008-03       Impact factor: 3.275

Review 4.  Cost-effectiveness of vaccination against herpes zoster.

Authors:  Pieter T de Boer; Jan C Wilschut; Maarten J Postma
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.

Authors:  Mélanie Drolet; Zhou Zhou; Chantal Sauvageau; Philippe DeWals; Vladimir Gilca; Rachid Amini; Élodie Bénard; Marc Brisson
Journal:  CMAJ       Date:  2019-08-26       Impact factor: 8.262

6.  Herpes zoster and postherpetic neuralgia: an examination of psychological antecedents.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2014-05

Review 7.  Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions.

Authors:  Roland Staud
Journal:  Expert Rev Neurother       Date:  2012-05       Impact factor: 4.618

8.  Varicella-zoster virus-derived major histocompatibility complex class I-restricted peptide affinity is a determining factor in the HLA risk profile for the development of postherpetic neuralgia.

Authors:  Pieter Meysman; Benson Ogunjimi; Stefan Naulaerts; Philippe Beutels; Viggo Van Tendeloo; Kris Laukens
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

9.  Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.

Authors:  Alies van Lier; Albert Jan van Hoek; Wim Opstelten; Hein J Boot; Hester E de Melker
Journal:  BMC Health Serv Res       Date:  2010-08-13       Impact factor: 2.655

10.  Chloroquine diphosphate: a risk factor for herpes zoster in patients with dermatomyositis/polymyositis.

Authors:  Gilmara Franco da Cunha; Fernando Henrique Carlos de Souza; Maurício Levy-Neto; Samuel Katsuyuki Shinjo
Journal:  Clinics (Sao Paulo)       Date:  2013-05       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.